Cell and Gene Therapy Regulatory Pathway: FDA Requirements Guide
Cell and gene therapy (CGT) products are regulated by FDA's Center for Biologics Evaluation and Research (CBER) under Section 351 of the Public Health Service Act. They require an Investigational New Drug (IND) application for clinical trials and a Biologics License Application (BLA) for marketing approval. CGT products face unique CMC requirements for viral vectors, cell banks, and potency assays, and are eligible for expedited programs including RMAT designation, breakthrough therapy designation, and accelerated approval.
Key Takeaways
Key Takeaways
- CGT products are regulated by CBER under Section 351 of the Public Health Service Act and require BLA approval, not NDA.
- FDA anticipates receiving over 200 IND applications annually for CGT products, with more than 30 approved as of early 2026.
- Unique CMC challenges include viral vector manufacturing, cell bank characterization, potency assay development, and raw material qualification.
- Expedited programs (RMAT designation, breakthrough therapy, accelerated approval) are commonly applicable to CGT products addressing serious conditions.
- Cell and gene therapy products represent one of the most complex regulatory categories at FDA. These products include gene therapies using viral vectors (AAV, lentivirus), ex vivo genetically modified cells (CAR-T), somatic cell therapies, and gene editing technologies. Each product type introduces distinct manufacturing, characterization, and clinical challenges that require specialized regulatory strategies.
- CBER's Office of Therapeutic Products (OTP), reorganized in 2020 from the former Office of Tissues and Advanced Therapies (OTAT), oversees the review of CGT applications. As of early 2026, FDA has approved over 30 cell and gene therapy products, and the agency's own projections anticipate receiving more than 200 IND applications annually for CGT products.
- In this guide, you will learn:
- How FDA classifies and regulates cell and gene therapy products
- IND requirements specific to CGT products
- CMC considerations for viral vectors, cell banks, and potency assays
- Preclinical study expectations for CGT
- Expedited programs available for CGT developers
- Key FDA guidance documents governing cell and gene therapy
- ---
What Are Cell and Gene Therapy Products? FDA Classification Framework
Cell and gene therapy products are biological products that introduce genetic material into a patient's cells to replace, repair, or modify gene expression (gene therapy), or use cells as the therapeutic agent, whether autologous or allogeneic, manipulated or combined with other components (cell therapy). FDA regulates these under the Public Health Service Act, Section 351, as biological products requiring BLA approval.
FDA draws a critical regulatory distinction between cell and gene therapy products and the broader category of human cells, tissues, and cellular and tissue-based products (HCT/Ps) regulated under 21 CFR Part 1271.
Regulatory Classification Decision Tree
| Question | If Yes | If No |
|---|---|---|
| Is the product more than minimally manipulated? | Regulated as biological product (351 BLA required) | Continue assessment |
| Is it intended for homologous use only? | May qualify as 361 HCT/P (no BLA needed) | Regulated as biological product |
| Is it combined with another article (drug, device)? | Regulated as biological product or combination | Continue assessment |
| Does it have systemic effect or depend on metabolic activity? | Regulated as biological product | May qualify as 361 HCT/P |
Products that meet all four criteria under 21 CFR 1271.10 are regulated solely under Section 361 of the PHS Act and do not require premarket approval. Products that fail any criterion are regulated under Section 351 and require an IND for clinical investigation and a BLA for marketing.
Major Categories of CGT Products
| Category | Examples | Vector/Delivery | Regulatory Considerations |
|---|---|---|---|
| In vivo gene therapy | AAV-based (Zolgensma, Luxturna), lentiviral | Viral vectors administered directly | Vector biodistribution, long-term follow-up, immunogenicity |
| Ex vivo gene-modified cells | CAR-T (Kymriah, Yescarta), gene-edited cells | Cells modified outside body, reinfused | Chain of identity/custody, starting material variability |
| Somatic cell therapy | Expanded stem cells, dendritic cell therapies | No genetic modification | Minimal manipulation determination, potency |
| Gene editing | CRISPR-based therapies (Casgevy) | Ribonucleoprotein, viral delivery | Off-target analysis, genotoxicity |
| Oncolytic virus therapy | Imlygic (T-VEC) | Replication-competent virus | Shedding studies, environmental risk |
As of March 2026, FDA has approved 37 cell and gene therapy products, including 7 CAR-T products, 4 AAV gene therapies, and the first CRISPR-based gene editing therapy (Casgevy, approved December 2023). CBER receives approximately 200+ IND applications per year for CGT products.
Cell and Gene Therapy FDA: IND Requirements for CGT Products
Filing an IND for a cell and gene therapy product follows the standard 21 CFR 312 framework but with additional expectations documented in multiple FDA guidance documents specific to CGT.
IND Content Requirements for CGT
The IND must include the standard components under 21 CFR 312.23 but with CGT-specific emphasis:
| IND Section | Standard Content | CGT-Specific Additions |
|---|---|---|
| Form FDA 1571 | Cover sheet, investigator info | Indicate CBER as receiving center |
| Table of Contents | Organized per 21 CFR 312.23 | Reference applicable CGT guidance |
| Introductory Statement | Drug name, structure, route | Vector type, transgene, mechanism of action |
| Chemistry, Manufacturing, and Controls | Drug substance, drug product specs | Vector characterization, cell bank testing, potency assays |
| Pharmacology/Toxicology | Animal efficacy, safety | Biodistribution, tumorigenicity, germline transmission |
| Clinical Protocol | Phase 1 design, endpoints | Dose escalation rationale, long-term follow-up plan |
| Investigator's Brochure | Compiled nonclinical/clinical data | CGT-specific risk assessment |
Pre-IND Meeting for CGT Products
FDA strongly recommends a pre-IND meeting (Type B) for CGT products. The meeting request should be submitted under 21 CFR 312.82 and should address:
- Product characterization strategy including critical quality attributes
- Manufacturing process including vector production and purification
- Preclinical study design including animal model selection
- Clinical trial design including dose selection rationale
- Long-term follow-up plans per FDA recommendations
Submit the pre-IND meeting request with a detailed briefing document at least 30 days before the requested meeting date. Include specific questions organized by CMC, nonclinical, and clinical topics. CBER's OTP typically grants pre-IND meetings for novel CGT products and provides written responses even when a face-to-face meeting is not granted.
Key FDA Guidance Documents for CGT INDs
| Guidance Document | Year | Key Content |
|---|---|---|
| Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs) | 2020 | Master guidance for CGT CMC |
| Preclinical Assessment of Investigational Cellular and Gene Therapy Products | 2013 | Nonclinical study design |
| Long Term Follow-Up After Administration of a Gene Therapy Product | 2020 | 5-15 year follow-up expectations |
| Human Gene Therapy for Rare Diseases | 2020 | Specific considerations for orphan CGT |
| Human Gene Therapy for Retinal Disorders | 2020 | Indication-specific guidance |
| Human Gene Therapy for Hemophilia | 2020 | Indication-specific guidance |
| Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products | 2015 | Phase 1 trial design |
| Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up | 2020 | RCR/RCL testing |
CGT Regulatory Requirements: Chemistry, Manufacturing, and Controls
The CMC section of a CGT IND or BLA is the most complex and scrutinized component. FDA's 2020 guidance on CMC for gene therapy INDs (Docket FDA-2018-D-3434) provides the framework.
Drug Substance: Vector Characterization
For gene therapy products, the drug substance is typically the viral vector or the genetically modified cells.
Viral Vector Characterization Requirements:
| Attribute | Tests Required | Regulatory Basis |
|---|---|---|
| Identity | Restriction enzyme mapping, sequencing of transgene and regulatory elements | 21 CFR 610.14 |
| Purity | Host cell protein, host cell DNA, residual plasmid DNA, residual benzonase | USP <1043>, FDA CMC guidance |
| Potency | Functional assay measuring biological activity (transduction efficiency, transgene expression) | 21 CFR 610.10 |
| Quantity/Titer | Genome copies (qPCR), infectious titer, particle-to-infectivity ratio | FDA CMC guidance |
| Safety | Sterility (21 CFR 610.12), mycoplasma, adventitious agents, endotoxin, replication-competent virus | 21 CFR 610, USP <71>, <85> |
| Aggregation | Analytical ultracentrifugation, DLS, SEC | FDA CMC guidance |
Cell Bank Testing
For products using cell banks (both master cell bank and working cell bank), testing must demonstrate:
| Test Category | MCB Testing | WCB Testing | End-of-Production Cells |
|---|---|---|---|
| Sterility | Required | Required | Required |
| Mycoplasma | Required | Required | Required |
| Identity | Isoenzyme, STR, karyology | STR | Not typically required |
| Adventitious viruses | In vitro and in vivo assays, species-specific retroviruses | Abbreviated panel | In vitro assay |
| Retrovirus | Electron microscopy, reverse transcriptase, PCR-based | Abbreviated | Required for some |
| Karyology | G-banding at MCB and limit of in vitro cell age | Not typically | At limit of cell age |
Potency Assays for CGT Products
Potency is defined under 21 CFR 600.3(s) as the specific ability or capacity of a product to effect a given result. For CGT products, potency assays present unique challenges.
| Product Type | Potency Assay Approaches | FDA Expectation |
|---|---|---|
| AAV gene therapy | Transgene expression in relevant cell line, vector genome titer | Quantitative biological assay preferred; surrogate acceptable for Phase 1 |
| CAR-T | Cytotoxicity against target cells, cytokine release, CAR expression | Matrix of assays reflecting mechanism; single assay rarely sufficient |
| Lentiviral vector | Transduction efficiency, transgene expression, integration copy number | Functional assay required by Phase 3 |
| Gene editing | On-target editing efficiency, indel frequency, protein expression | Editing efficiency plus functional readout |
FDA expects a potency assay strategy that matures over development. A surrogate assay (e.g., vector titer) may be acceptable at the IND stage, but a biological activity-based assay measuring the product's mechanism of action is expected by the time of BLA submission. Document your potency assay development plan in the IND and discuss it at pre-IND meetings.
Comparability for Manufacturing Changes
Manufacturing changes during CGT development are common and require comparability assessments per FDA's Comparability Protocols guidance and ICH Q5E. Key considerations include:
- Analytical comparability using the full panel of release tests plus extended characterization
- Functional comparability using potency assays
- Clinical bridging may be required for major changes (new cell line, different vector serotype, scale changes affecting product quality)
- FDA may request additional nonclinical studies if analytical comparability is inconclusive
Preclinical Expectations for Cell and Gene Therapy Products
FDA's 2013 guidance "Preclinical Assessment of Investigational Cellular and Gene Therapy Products" outlines the nonclinical framework. The goal is to provide adequate evidence of safety to support initial clinical dosing.
Animal Model Selection
| Consideration | Requirement | Rationale |
|---|---|---|
| Species relevance | Use species in which the product is biologically active | Ensures pharmacology data is meaningful |
| Disease model | Preferred but not required | Enhances translatability; healthy animal studies acceptable |
| Immunological response | Consider immunocompetent vs. immunodeficient | Immunocompetent preferred for immunogenicity assessment |
| Route of administration | Match clinical route | Required for relevant safety assessment |
Required Preclinical Studies
| Study Type | Purpose | Duration | Key Endpoints |
|---|---|---|---|
| Proof of concept | Demonstrate biological activity in relevant model | Variable | Transgene expression, functional outcome |
| Biodistribution | Determine where vector/cells distribute after administration | Acute through 3-6 months minimum | qPCR of vector genomes in target and non-target tissues |
| Toxicology | Identify target organs, dose-limiting toxicity | Single dose with follow-up through 3-6 months | Histopathology, clinical pathology, organ weights |
| Tumorigenicity | Assess oncogenic potential (integrating vectors) | 6-12 months or longer | Tumor formation, integration site analysis |
| Shedding | For replication-competent or high-titer vectors | Through clearance | Vector in secretions, excreta |
| Germline transmission | Assess risk of inadvertent germline modification | Part of biodistribution | Vector in gonads |
Biodistribution Studies: Specific Requirements
Biodistribution studies are critical and often the most extensive nonclinical studies for CGT products.
FDA expectations for biodistribution:
- Evaluate vector DNA in blood, injection site, gonads, brain, heart, kidneys, liver, lungs, spleen, and any target tissue
- Use quantitative PCR (qPCR) with validated methods and appropriate sensitivity (limit of detection defined)
- Include multiple time points to characterize kinetics of distribution and persistence
- Sacrifice sufficient animals at each time point for statistical analysis
- If vector persists in gonads, additional germline transmission assessment is required
According to FDA's 2013 preclinical guidance, biodistribution data should include at minimum 3 animals per sex per time point, with a minimum of 3 time points spanning early (24-72 hours), intermediate (14-28 days), and late (3-6 months) assessment.
Expedited Programs for CGT: RMAT, Breakthrough Therapy, and Accelerated Approval
Cell and gene therapy products are eligible for several FDA expedited programs, with RMAT designation being particularly relevant.
Regenerative Medicine Advanced Therapy (RMAT) Designation
RMAT designation was established by Section 3033 of the 21st Century Cures Act (December 2016) and is codified at Section 506(g) of the FD&C Act.
RMAT Eligibility Criteria:
- The product is a regenerative medicine therapy (cell therapy, therapeutic tissue engineering, human cell and tissue product, or gene therapy, including genetically modified cells)
- The product is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition
- Preliminary clinical evidence indicates potential to address unmet medical needs for the disease or condition
| RMAT Feature | Description |
|---|---|
| All Fast Track and Breakthrough benefits | Frequent meetings, rolling review, priority review, intensive guidance |
| Accelerated approval eligibility | Based on surrogate or intermediate clinical endpoints reasonably likely to predict long-term clinical benefit |
| Priority review eligibility | 6-month review instead of standard 10-month |
| Post-approval requirements | May include surrogate endpoints with confirmatory studies |
Comparison of Expedited Programs for CGT
| Feature | RMAT | Breakthrough Therapy | Fast Track | Accelerated Approval |
|---|---|---|---|---|
| Eligible products | Regenerative medicine therapies only | Any drug/biologic | Any drug/biologic | Any drug/biologic |
| Condition requirement | Serious or life-threatening | Serious or life-threatening | Serious condition with unmet need | Serious condition |
| Evidence requirement | Preliminary clinical evidence of potential | Preliminary clinical evidence of substantial improvement | Nonclinical or clinical data | Surrogate/intermediate endpoint |
| Rolling review | Yes | Yes | Yes | N/A (approval mechanism) |
| Intensive FDA guidance | Yes | Yes | No | N/A |
| Priority review | Eligible | Eligible | Not automatic | Not automatic |
| Can be combined | Yes, with BT and AA | Yes, with RMAT | Yes, with BT and RMAT | Yes, as approval pathway |
CGT developers should consider requesting both RMAT and breakthrough therapy designations simultaneously. They are not mutually exclusive, and dual designation maximizes available benefits. The RMAT request is submitted to CBER under the IND, and the evidentiary requirements overlap significantly with breakthrough therapy requests.
Accelerated Approval for CGT Products
Several CGT products have been approved under accelerated approval (21 CFR Part 601, Subpart H for biologics) based on surrogate or intermediate clinical endpoints:
| Product | Indication | Surrogate Endpoint | Year |
|---|---|---|---|
| Abecma (idecabtagene) | Multiple myeloma | Overall response rate | 2021 |
| Breyanzi (lisocabtagene) | Large B-cell lymphoma | Overall response rate, complete response rate | 2021 |
| Carvykti (ciltacabtagene) | Multiple myeloma | Overall response rate | 2022 |
Accelerated approval requires post-marketing confirmatory studies under 21 CFR 601.41, and FDA has authority under the Accelerated Approval Integrity Act (part of FDORA, P.L. 117-328, enacted December 2022) to withdraw approval if confirmatory studies fail.
Gene Therapy BLA: Submission Requirements and eCTD Structure
The BLA for gene therapy products follows the standard eCTD format under 21 CFR 601 and ICH M4 but with CGT-specific content expectations.
eCTD Module Structure for CGT BLA
| Module | Standard Content | CGT-Specific Content |
|---|---|---|
| Module 1 | Administrative (Form 356h, labeling, patent info) | REMS if required, pediatric study plans, environmental assessment |
| Module 2 | Summaries (QOS, nonclinical, clinical) | Emphasis on product characterization, potency strategy, long-term follow-up summary |
| Module 3 (CMC) | Drug substance, drug product, reference standards | Vector characterization, cell bank documentation, potency assays, comparability, viral clearance |
| Module 4 | Nonclinical study reports | Biodistribution, tumorigenicity, integration site analysis, shedding studies |
| Module 5 | Clinical study reports | Efficacy, safety, immunogenicity, long-term follow-up data |
Module 3 Specifics for CGT BLA
Module 3 for a CGT BLA is substantially more complex than for small molecules or conventional biologics.
Drug Substance (3.2.S):
- Complete description of the manufacturing process including cell culture, transfection/infection, harvest, purification
- Raw material and starting material specifications
- Process validation for at least 3 consecutive lots at commercial scale
- Viral clearance/inactivation studies (for products not intended to contain live virus)
- Container closure system qualification
Drug Product (3.2.P):
- Formulation development including excipient justification
- Final container fill and finish process
- Stability data per ICH Q5C (stability of biotechnological products)
- Shipping and storage validation including cold chain documentation
- Specification justification based on manufacturing experience and clinical lots
Long-Term Follow-Up Requirements
FDA's 2020 guidance on long-term follow-up (LTFU) applies to all gene therapy products and specifies:
| Vector Type | Recommended LTFU Duration | Rationale |
|---|---|---|
| Integrating vectors (lentivirus, retrovirus) | 15 years | Risk of insertional mutagenesis, oncogenesis |
| AAV vectors | 5 years (may extend to 15) | Persistence of transgene expression, delayed adverse events |
| Gene editing (CRISPR, ZFN, TALEN) | 15 years | Off-target effects, long-term consequences of permanent genome modification |
| Non-integrating, non-persisting | Case-by-case, minimum 5 years | Based on product-specific risk assessment |
LTFU observations include annual physical examination, monitoring for new malignancies, hematologic abnormalities (for integrating vectors), and assessment of transgene expression persistence.
FDA's recommended long-term follow-up period for integrating gene therapy vectors is 15 years post-treatment, reflecting the latency period observed for insertional oncogenesis in early gene therapy trials (the X-SCID trials in France, where leukemia developed 2-5 years post-treatment).
Environmental Assessment Requirements
Gene therapy INDs and BLAs require an environmental assessment (EA) under 21 CFR 25 unless a categorical exclusion applies. This is unique among biologic products.
When an EA Is Required
| Scenario | EA Required? | Basis |
|---|---|---|
| Non-replicating vector, contained use | Categorical exclusion may apply (21 CFR 25.31) | No significant environmental release expected |
| Replication-competent vector | EA required | Potential for environmental release and spread |
| Shedding of vector in patient excreta | EA typically required | Environmental exposure pathway exists |
| Gene drive or environmental release applications | Full Environmental Impact Statement may be needed | Significant environmental impact possible |
The EA must evaluate the potential for environmental release of the vector, risks to non-target organisms, and mitigation measures.
Frequently Asked Questions About CGT Regulatory Pathways
Does CBER or CDER regulate gene therapy?
CBER's Office of Therapeutic Products (OTP) regulates gene therapy, cell therapy, and related products. CDER reviews most therapeutic biologics including monoclonal antibodies. The Intercenter Agreement between CBER and CDER defines jurisdiction, with CBER handling vaccines, blood products, allergenic products, and cell and gene therapies, while CDER handles most therapeutic proteins.
Can gene therapy products receive orphan drug designation?
Yes. Gene therapy products are eligible for orphan drug designation under the Orphan Drug Act (21 CFR 316) if intended to treat a condition affecting fewer than 200,000 persons in the US. Orphan designation provides 7 years of market exclusivity, tax credits for clinical research, and waiver of PDUFA application fees. Many approved CGT products hold orphan designation due to the rare disease focus of early gene therapies.
What is the BLA review timeline for CGT products?
Standard BLA review under PDUFA is 10 months from the filing date (60-day filing review plus 10-month review clock). Priority review reduces this to 6 months. Many CGT products receive priority review through breakthrough therapy or RMAT designation. The 60-day filing review period applies regardless of priority review status.
Are combination products involving CGT possible?
Yes. Some CGT products are combination products (e.g., cells seeded on a scaffold device). These are regulated under 21 CFR Part 3 with assignment to a lead center (usually CBER for CGT combinations). The primary mode of action determines the lead center, and an intercenter consult addresses the other component.
What post-market requirements apply to approved CGT products?
Post-market requirements include annual BLA reports (21 CFR 601.12), adverse event reporting (21 CFR 600.80), manufacturing change supplements, long-term follow-up studies, REMS implementation if required, and any post-marketing commitments or requirements from the approval letter.
Key Regulatory References
| Reference | Citation |
|---|---|
| Public Health Service Act, Section 351 | 42 U.S.C. 262 |
| IND Regulations | 21 CFR Part 312 |
| BLA Regulations | 21 CFR Part 601 |
| Biologics Standards | 21 CFR Parts 600-680 |
| HCT/P Regulations | 21 CFR Part 1271 |
| Environmental Assessment | 21 CFR Part 25 |
| 21st Century Cures Act (RMAT) | Section 3033, P.L. 114-255 |
| FDA CMC Guidance for Gene Therapy INDs | January 2020 |
| FDA Preclinical Assessment Guidance for CGT | November 2013 |
| FDA Long-Term Follow-Up Guidance | January 2020 |
| ICH Q5C Stability of Biotechnological Products | 1995 (current) |
| ICH Q5E Comparability of Biotechnological Products | 2004 (current) |
References
Sources
- Public Health Service Act, Section 351 (42 U.S.C. 262)
- 21 CFR Part 312 - IND Regulations
- 21 CFR Part 601 - BLA Regulations
- 21 CFR Part 1271 - HCT/P Regulations
- FDA Guidance: Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy INDs (January 2020)
- FDA Guidance: Long Term Follow-Up After Administration of Human Gene Therapy Products (January 2020)
- 21st Century Cures Act, Section 3033 - RMAT Designation (P.L. 114-255)